QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.
29 Citations
83 Claims
-
1. A compound having the formula:
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83)
-
2. The compound of claim 1,
wherein, Q is (CHR6)1-3; -
R1 and each R6 is, independently, H, optionally substituted C1-6 alkyl, optionally substituted C1-4 alkaryl, optionally substituted C1-4 alkheterocyclyl, or optionally substituted C2-9 heterocyclyl; each of R2 and R3 is, independently, H, Hal, optionally substituted C1-6 alkyl, optionally substituted C6-10 aryl, optionally substituted C1-6 alkaryl, optionally substituted C2-9 heterocyclyl, or optionally substituted C1-4 alkheterocyclyl; each of R4 and R5 is, independently, H, (CH2)r2NHC(NH)R2A, or (CH2)r2NHC(S)NHR2A wherein Y1 and Y2 are each H, or Y1 and Y2 together are ═
O;wherein one, but not both, of R4 and R5 is H; or a pharmaceutically acceptable salt or prodrug thereof.
-
-
3. The compound of claim 1, wherein Y1 and Y2 together are ═
- O, and Q is (CHR6)2.
-
4. The compound of claim 1, wherein Y1 and Y2 are each H, and Q is (CHR6)2.
-
5. The compound of claim 1, wherein Y1 and Y2 together are ═
- O, and Q is CHR6.
-
6. The compound of claim 1, wherein Y1 and Y2 are each H, and Q is CHR6.
-
7. The compound of claim 1, wherein Y1 and Y2 together are ═
- O, and Q is (CHR6)3.
-
8. The compound of claim 1, wherein Y1 and Y2 are each H, and Q is (CHR6)3.
-
9. The compound of claims 1, wherein R4 or R5 has the formula:
-
10. The compound of claim 9, wherein R2A has the formula:
-
11. The compound of claim 10, wherein R2A has the formula:
-
12. The compound of claims 1, wherein R2 or R3 has the formula:
-
13. The compound of claim 12, wherein R2A has the formula:
-
14. The compound of claim 13, wherein R2A has the formula:
-
15. The compound of claim 11, wherein X1 is CH and X2 is S.
-
16. The compound of claim 14, wherein X1 is CH and X2 is S.
-
17. The compound of claim 1, wherein said compound has the formula of:
-
18. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient.
-
19. A method of treating or preventing a condition in a mammal caused by the action of nitric oxide synthase (NOS), wherein said method comprises administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or prodrug thereof to said mammal.
-
20. The method of claim 19, wherein said mammal is a human.
-
21. The method of claim 19, wherein said condition is migraine headache (with or without aura), chronic tension type headache (CTTH), migraine with allodynia, medication overuse headache, neuropathic pain, AIDS associated painful neuropathy, chronic headache, central post-stroke pain (CPSP), medication-induced hyperalgesia or allodynia, acute pain, chronic pain, diabetic neuropathy, trigeminal neuralgia, chemotherapy induced neuropathic pain, bone cancer pain, chemical dependencies or addictions, CNS disorders, neurodegenerative diseases or nerve injury, cardiovascular related conditions, diabetic nephropathy, inflammatory diseases, or gastrointestinal disorders.
-
22. The method of claim 21, wherein said medication-induced hyperalgesia or allodynia is opioid-induced hyperalgesia/allodynia or triptan (5-HT1D/1B agonists)-induced hyperalgesia or allodynia.
-
23. The method of claim 21, wherein said chemotherapy induced neuropathic pain is induced by Paclitaxol, cis-Platin, or Doxorubicin.
-
24. The method of claim 21, wherein said chemical dependency or addiction is drug addiction, cocaine addiction, nicotine addiction, methamphetamine-induced neurotoxicity, ethanol tolerance, dependence, or withdrawal, or morphine/opioid induced tolerance, dependence, hyperalgesia, or withdrawal.
-
25. The method of claim 21, wherein said CNS disorder is epilepsy, anxiety, depression, attention deficit hyperactivity disorder (ADHD), psychosis, or dementia.
-
26. The method of claim 21, wherein said neurodegenerative disease or nerve injury is acute spinal cord injury, AIDS associated dementia, Parkinson'"'"'s disease, Alzheimer'"'"'s disease, amyotrophic lateral sclerosis (ALS), Huntington'"'"'s disease, multiple sclerosis, neurotoxicity, or head trauma.
-
27. The method of claim 21, wherein said cardiovascular related condition is stroke, coronary artery bypass graft (CABG) associated neurological damage, hypothermic cardiac arrest (HCA), post-stroke pain, cardiogenic shock, reperfusion injury, or vascular dementia.
-
28. The method of claim 21, wherein said inflammatory disease is osteoarthritis or neuroinflammation.
-
29. The method of claim 21, wherein said gastrointestinal disorder is ileostomy-associated diarrhea, dumping syndrome, or visceral pain.
-
30. The method of claim 21, wherein said condition is stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, chronic tension type headache, neuropathic pain, central post-stroke pain (CPSP), morphine/opioid induced hyperalgesia or chronic pain.
-
31. The method of claim 19, wherein said condition is central post-stroke pain (CPSP).
-
32. The method of claim 19, wherein said method further comprises administering to said mammal an opioid.
-
33. The method of claim 32, wherein said opioid is alfentanil, butorphanol, buprenorphine, dextromoramide, dezocine, dextropropoxyphene, codeine, dihydrocodeine, diphenoxylate, etorphine, fentanyl, hydrocodone, hydromorphone, ketobemidone, loperamide, levorphanol, levomethadone, meperidine, meptazinol, methadone, morphine, morphine-6-glucuronide, nalbuphine, naloxone, oxycodone, oxymorphone, pentazocine, pethidine, piritramide, propoxyphene, remifentanil, sulfentanyl, tilidine, and tramadol.
-
34. The method of claim 19, wherein said method further comprises administering to said mammal an antidepressant.
-
35. The method of claim 34, wherein said antidepressant is a selective serotonin re-uptake inhibitor.
-
36. The method of claim 35, wherein said selective serotonin re-uptake inhibitor is citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline.
-
37. The method of claim 34, wherein said antidepressant is a norepinephrine-reuptake inhibitor.
-
38. The method of claim 37, wherein said norepinephrine-reuptake inhibitor is amitriptyline, desmethylamitriptyline, clomipramine, doxepin, imipramine, imipramine oxide, trimipramine;
- adinazolam, amiltriptylinoxide, amoxapine, desipramine, maprotiline, nortriptyline, protriptyline, amineptine, butriptyline, demexiptiline, dibenzepin, dimetacrine, dothiepin, fluacizine, iprindole, lofepramine, melitracen, metapramine, norclolipramine, noxiptilin, opipramol, perlapine, pizotyline, propizepine, quinupramine, reboxetine, or tianeptine.
-
39. The method of claim 34, wherein said antidepressant is a selective noradrenaline/norepinephrine reuptake inhibitor.
-
40. The method of claim 39, wherein selective noradrenaline/norepinephrine reuptake inhibitor is atomoxetine, bupropion, reboxetine, or tomoxetine.
-
41. The method of claim 34, wherein said antidepressant is a dual serotonin/norepinephrine reuptake inhibitor.
-
42. The method of claim 41, wherein said dual serotonin/norepinephrine reuptake inhibitor is duloxetine, milnacipran, mirtazapine, nefazodone, or venlafaxine.
-
43. The method of claim 34, wherein said antidepressant is a monoamine oxidase inhibitor.
-
44. The method of claim 43, wherein said monoamine oxidase inhibitor is amiflamine, iproniazid, isocarboxazid, M-3-PPC (Draxis), moclobemide, pargyline, phenelzine, tranylcypromine, or vanoxerine.
-
45. The method of claim 34, wherein said antidepressant is a reversible monoamine oxidase type A inhibitor.
-
46. The method of claim 45, wherein said reversible monoamine oxidase type A inhibitor is bazinaprine, befloxatone, brofaromine, cimoxatone, or clorgyline.
-
47. The method of claim 34, wherein said antidepressant is a tricyclic.
-
48. The method of claim 47, wherein said tricyclic is amitriptyline, clomipramine, desipramine, doxepin, imipramine, maprotiline, nortriptyline, protriptyline, or trimipramine.
-
49. The method of claim 34, wherein said antidepressant is adinazolam, alaproclate, amineptine, amitriptyline/chlordiazepoxi-de combination, atipamezole, azamianserin, bazinaprine, befuraline, bifemelane, binodaline, bipenamol, brofaromine, caroxazone, cericlamine, cianopramine, cimoxatone, citalopram, clemeprol, clovoxamine, dazepinil, deanol, demexiptiline, dibenzepin, dothiepin, droxidopa, enefexine, estazolam, etoperidone, femoxetine, fengabine, fezolamine, fluotracen, idazoxan, indalpine, indeloxazine, iprindole, levoprotiline, lithium, litoxetine;
- lofepramine, medifoxamine, metapramine, metralindole, mianserin, milnacipran, minaprine, mirtazapine, montirelin, nebracetam, nefopam, nialamide, nomifensine, norfluoxetine, orotirelin, oxaflozane, pinazepam, pirlindone, pizotyline, ritanserin, rolipram, sercloremine, setiptiline, sibutramine, sulbutiamine, sulpiride, teniloxazine, thozalinone, thymoliberin, tianeptine, tiflucarbine, trazodone, tofenacin, tofisopam, toloxatone, tomoxetine, veralipride, viloxazine, viqualine, zimelidine, or orzometrapine.
-
50. The method of claim 19, wherein said method further comprises administering to said mammal an antiepileptic.
-
51. The method of claim 50, wherein said antiepileptic is carbamazepine, flupirtine, gabapentin, lamotrigine, oxcarbazepine, phenyloin, retigabine, topiramate, or valproate.
-
52. The method of claim 19, wherein said method further comprises administering to said mammal a non-steroidal anti-inflammatory drug (NSAID) or acetaminophen.
-
53. The method of claim 52, wherein said NSAID is acemetacin, aspirin, celecoxib, deracoxib, diclofenac, diflunisal, ethenzamide, etofenamate, etoricoxib, fenoprofen, flufenamic acid, flurbiprofen, lonazolac, lornoxicam, ibuprofen, indomethacin, isoxicam, kebuzone, ketoprofen, ketorolac, naproxen, nabumetone, niflumic acid, sulindac, tolmetin, piroxicam, meclofenamic acid, mefenamic acid, meloxicam, metamizol, mofebutazone, oxyphenbutazone, parecoxib, phenidine, phenylbutazone, piroxicam, propacetamol, propyphenazone, rofecoxib, salicylamide, suprofen, tiaprofenic acid, tenoxicam, valdecoxib, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, and 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one).
-
54. The method of claim 19, wherein said method further comprises administering to said mammal an antiarrhythmic.
-
55. The method of claim 19, wherein said method further comprises administering to said mammal a GABA-B antagonist.
-
56. The method of claim 19, wherein said method further comprises administering to said mammal an alpha-2-adrenergic receptor agonist.
-
57. The method of claim 19, wherein said method further comprises administering to said mammal a serotonin 5HT1B/1D agonist.
-
58. The method of claim 57, wherein said serotonin 5HT1B/1D agonist is eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, donitriptan, or zolmitriptan.
-
59. The method of claim 19, wherein said method further comprises administering to said mammal an N-methyl-D-aspartate antagonist or glutamate receptor antagonist.
-
60. The method of claim 59, wherein said N-methyl-D-aspartate antagonist or glutamate receptor antagonist is amantadine;
- aptiganel;
besonprodil;
budipine;
conantokin G;
delucemine;
dexanabinol;
dextromethorphan;
dextropropoxyphen;
felbamate;
fluorofelbamate;
gacyclidine;
glycine;
ipenoxazone;
kaitocephalin;
ketamine;
ketobemidone;
lanicemine;
licostinel;
midafotel;
memantine;
D-methadone;
D-morphine;
milnacipran;
neramexane;
orphenadrine;
remacemide;
sulfazocine;
FPL-12,495 (racemide metabolite);
topiramate;
(α
R)-α
-amino-5-chloro-1-(phosphonomethyl)-1H-benzimidazole-2-propanoic acid;
1-aminocyclopentane-carboxylic acid;
[5-(aminomethyl)-2-[[[(5S)-9-chloro-2,3,6,7-tetrahydro-2,3-dioxo-1H,5H-pyrido[1,2,3-de]quinoxalin-5-yl]acetyl]amino]phenoxy]-acetic acid;
α
-amino-2-(2-phosphonoethyl)-cyclohexanepropanoic acid;
α
-amino-4-(phosphonomethyl)-benzeneacetic acid;
(3E)-2-amino-4-(phosphonomethyl)-3-heptenoic acid;
3-[(1E)-2-carboxy-2-phenylethenyl]-4,6-dichloro-1H-indole-2-carboxylic acid;
8-chloro-2,3-dihydropyridazino[4,5-b]quinoline-1,4-dione 5-oxide salt with 2-hydroxy-N,N,N-trimethyl-ethanaminium;
N′
-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]-guanidine;
N′
-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-[(R)-methylsulfinyl]phenyl]-guanidine;
6-chloro-2,3,4,9-tetrahydro-9-methyl-2,3-dioxo-1H-indeno[1,2-b]pyrazine-9-acetic acid;
7-chlorothiokynurenic acid;
(3S,4aR,6S,8aR)-decahydro-6-(phosphonomethyl)-3-isoquinolinecarboxylic acid;
(−
)-6,7-dichloro-1,4-dihydro-5-[3-(methoxymethyl)-5-(3-pyridinyl)-4-H-1,2,4-triazol-4-yl]-2,3-quinoxalinedione;
4,6-dichloro-3-[(E)-(2-oxo-1-phenyl-3-pyrrolidinylidene)methyl]-1H-indole-2-carboxylic acid;
(2R,4S)-rel-5,7-dichloro-1,2,3,4-tetrahydro-4-[[(phenylamino)carbonyl]amino]-2-quinolinecarboxylic acid;
(3R,4S)-rel-3,4-dihydro-3-[4-hydroxy-4-(phenylmethyl)-1-piperidinyl]-2H-1-benzopyran-4,7-diol;
2-[(2,3-dihydro-1H-inden-2-yl)amino]-acetamide;
1,4-dihydro-6-methyl-5-[(methylamino)methyl]-7-nitro-2,3-quinoxalinedione;
[2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]-phosphonic acid;
(2R,6S)-1,2,3,4,5,6-hexahydro-3-[(2S)-2-methoxypropyl]-6,11,11-trimethyl-2,6-methano-3-benzazocin-9-ol;
2-hydroxy-5-[[(pentafluorophenyl)methyl]amino]-benzoic acid;
1-[2-(4-hydroxyphenoxy)ethyl]-4-[(4-methylphenyl)methyl]-4-piperidinol;
1-[4-(1H-imidazol-4-yl)-3-butynyl]-4-(phenylmethyl)-piperidine;
2-methyl-6-(phenylethynyl)-pyridine;
3-(phosphonomethyl)-L-phenylalanine;
or 3,6,7-tetrahydro-2,3-dioxo-N-phenyl-1H,5H-pyrido[1,2,3-de]quinoxaline-5-acetamide.
- aptiganel;
-
61. The method of claim 19, wherein said method further comprises administering to said mammal a cholecystokinin B antagonist.
-
62. The method of claim 19, wherein said method further comprises administering to said mammal a substance P antagonist.
-
63. The method of claim 19, wherein said method further comprises administering to said mammal an anti-inflammatory compound.
-
64. The method of claim 63, wherein said anti-inflammatory compound is aspirin, celecoxib, cortisone, deracoxib, diflunisal, etoricoxib, fenoprofen, ibuprofen, ketoprofen, naproxen, prednisolone, sulindac, tolmetin, piroxicam, mefenamic acid, meloxicam, phenylbutazone, rofecoxib, suprofen, valdecoxib, 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide, N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulfonamide, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methylbutoxy)-5-[4-(methylsulfonyl)phenyl]-3(2H)-pyridazinone, or 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one.
-
65. The method of claim 19, wherein said method further comprises administering to said mammal a DHP-sensitive L-type calcium channel antagonist, omega-conotoxin-sensitive N-type calcium channel antagonist, or a P/Q-type calcium channel antagonist.
-
66. The method of claim 19, wherein said method further comprises administering to said mammal an adenosine kinase antagonist.
-
67. The method of claim 19, wherein said method further comprises administering to said mammal an adenosine receptor A1 agonist, an adenosine receptor A2a antagonist or an adenosine receptor A3 agonist.
-
68. The method of claim 19, wherein said method further comprises administering to said mammal an adenosine deaminase inhibitor.
-
69. The method of claim 19, wherein said method further comprises administering to said mammal an adenosine nucleoside transport inhibitor.
-
70. The method of claim 19, wherein said method further comprises administering to said mammal a vanilloid VR1 receptor agonist.
-
71. The method of claim 19, wherein said method further comprises administering to said mammal a cannabinoid CB1/CB2 agonist.
-
72. The method of claim 19, wherein said method further comprises administering to said mammal an AMPA receptor antagonist.
-
73. The method of claim 19, wherein said method further comprises administering to said mammal a kainate receptor antagonist.
-
74. The method of claim 19, wherein said method further comprises administering to said mammal a sodium channel blocker.
-
75. The method of claim 19, wherein said method further comprises administering to said mammal a nicotinic acetylcholine receptor agonist.
-
76. The method of claim 19, wherein said method further comprises administering to said mammal a KATP potassium channel, Kv1.4 potassium channel, Ca2+-activated potassium channel, SK potassium channel, BK potassium channel, IK potassium channel, or KCNQ2/3 potassium channel opening agent.
-
77. The method of claim 19, wherein said method further comprises administering to said mammal a muscarinic M3 antagonist, a muscarinic M1 agonist, or a muscarinic M2/M3 partial agonist/antagonist.
-
78. The method of claim 19, wherein said method further comprises administering to said mammal an antioxidant.
-
79. The method of claim 19, wherein said method further comprises administering to said mammal an antipsychotic agent.
-
80. The method of claim 79, wherein said antipsychotic agent is promazine, chlorpromazine, chlorprothixene, thioridazine, acetophenazine, mesoridazine, droperidol, loxapine, molindone, perphenazine, prochlorphenazine, thiothixene, trifluoperazine, fluphenazine, pimozide, flupenthixol, methotrimeprazine, pipotiazine, sertindole, clozapine, olanzapine, risperidone, aripiprazole, quetiapine, haloperidol, ziprasidone, or iloperidone.
-
81. The method of claim 19, wherein said method further comprises administering to said mammal a dopamine receptor antiparkinson'"'"'s agent
-
82. The method of claim 81, wherein said antiparkinson'"'"'s agent is levodopa, or pramipexole.
-
83. The method of claim 19, wherein said method further comprises administering to said mammal Fatty Acid Amide Hydrolase (FAAH) Inhibitor.
-
2. The compound of claim 1,
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeNeurAxon, Inc. (Knight Therapeutics (Barbados) Inc.)
-
Original AssigneeNeurAxon, Inc. (Knight Therapeutics (Barbados) Inc.)
-
InventorsRenton, Paul, ANDREWS, John, ANNEDI, Subhash C., RAKHIT, Suman, DOVE, Peter, SILVERMAN, Sarah, RAMNAUTH, Jailall, PATMAN, Joanne, MADDAFORD, Shawn
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/165
-
CPC Class CodesA61P 1/00 Drugs for disorders of the ...A61P 13/12 of the kidneysA61P 19/02 for joint disorders, e.g. a...A61P 25/00 Drugs for disorders of the ...A61P 25/04 Centrally acting analgesics...A61P 25/06 Antimigraine agentsA61P 25/08 Antiepileptics; Anticonvuls...A61P 25/14 for treating abnormal movem...A61P 25/16 Anti-Parkinson drugsA61P 25/22 AnxiolyticsA61P 25/24 AntidepressantsA61P 25/28 for treating neurodegenerat...A61P 25/36 Opioid-abuseA61P 29/00 Non-central analgesic, anti...A61P 43/00 Drugs for specific purposes...A61P 9/00 Drugs for disorders of the ...C07D 409/12 linked by a chain containin...C07D 409/14 containing three or more he...C07D 413/14 containing three or more he...